NGNE - NASDAQ

Neurogene Inc.

Neurogene Inc.

NGNE·NASDAQ

$26.22

+0.31%
HealthcareBiotechnology

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$414.33M
EPS-4.2400
P/E Ratio-6.18
Earnings Date08/07/2026

Available Earnings Call Transcripts

Select a year and quarter to view the full transcript.

Neurogene Inc.

Neurogene Inc. Earnings Call Transcripts

NGNE · NASDAQ

No Transcripts Available

No earnings call transcripts found for ngne.

Related Guides

Blog Categories

Continue your NGNE research with focused valuation guides.

Forecasting

Compare management guidance with modeled outcomes.

Risk Analysis

Track estimate risk, misses, and downside scenarios.

Reference

Review analyst process and transcript interpretation.

Value Investing

Anchor quarterly narrative to intrinsic value discipline.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.